Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Combination reaction

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    220 result(s) found for: Combination reaction. Displaying page 1 of 11.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2011-006066-40 Sponsor Protocol Number: OZR-2011-23 Start Date*: 2012-05-15
    Sponsor Name:The Rotterdam Eye Hospital
    Full Title: The post-cataract inflammatory reaction with combination therapy of topical steroid and NSAID.
    Medical condition: Ocular inflammatory reaction after cataract surgery.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2021-002073-26 Sponsor Protocol Number: 1125-ECIR Start Date*: Information not available in EudraCT
    Sponsor Name:Medical Center - University of Freiburg
    Full Title: Phase 1/2 Trial to determine the safety and efficacy of Extracorporeal photopheresis as treatment for steroid-refractory immune related adverse events after immune checkpoint inhibitor therapy
    Medical condition: Immune related adverse events induced by treatment with immune checkpoint inhibitors (monoclocanl antibodies against PD-1, PD-L1 or CTLA-4)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10022117 - Injury, poisoning and procedural complications 10043408 Therapeutic agent toxicity LLT
    26.1 10018065 - General disorders and administration site conditions 10067033 Drug side effect LLT
    24.0 10018065 - General disorders and administration site conditions 10061623 Adverse drug reaction PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-001218-24 Sponsor Protocol Number: TDL-CS-001 Start Date*: 2014-06-05
    Sponsor Name:Trichocare Diagnostics Ltd
    Full Title: An open label, intra-subject, controlled multi-centre study to assess the concordance (specificity and sensitivity) between Colourstart® Test 73 mcg Cutaneous Patch and Finn Chamber in the detectio...
    Medical condition: Para-Phenylenediamine allergy
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004848 10065649 PPD skin test positive LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-005862-30 Sponsor Protocol Number: MHH-Pre-GvHD-001 Start Date*: 2009-02-23
    Sponsor Name:Medizinische Hochschule Hannover
    Full Title: Pre-emptive therapy of acute graft versus host disease according to specific proteomic patterns after allogeneic hematopoietic stem cell transplantation.
    Medical condition: Pre-emptive therapy of acute graft versus host disease with prednisolone according to specific proteomic patterns after allogeneic hematopoietic stem cell transplantation.
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004870 10018652 Graft versus host reaction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-002819-28 Sponsor Protocol Number: OCDDCS001 Start Date*: 2012-04-12
    Sponsor Name:Stockholms Läns Landsting
    Full Title: Internet-based cognitive behavior therapy in combination with D-Cycloserine for Obsessive Compulsive Disorder: A double blinded randomized controlled trial
    Medical condition: Obsessive Compulsive disorder
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10029898 Obsessive-compulsive disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2007-004806-28 Sponsor Protocol Number: C07-1 Start Date*: 2008-02-14
    Sponsor Name:GERCOR
    Full Title: An Open-label Phase II Clinical trial of Panitumumab in Combination with Irinotecan for Patients with Advanced Metastatic Colorectal Cancer without KRAS mutation (Wild type) in third line chemother...
    Medical condition: histologically confirmed Metastatic colorectal adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052358 Colorectal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2012-003191-39 Sponsor Protocol Number: Start Date*: 2013-01-21
    Sponsor Name:University of Oxford
    Full Title: The effect of a single-dose of d-cycloserine on the basic effects of cognitive-behaviour therapy for panic disorder - a randomized placebo-controlled trial
    Medical condition: DSM-IV Panic disorder
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004873 10068300 Panic attacks and disorders HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-001941-26 Sponsor Protocol Number: CA209-742 Start Date*: 2016-11-14
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Phase IIIb, Randomized, Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects with Previously Untreated Unresectable or Metastatic Melanoma
    Medical condition: Subjects with Previously Untreated Unresectable or Metastatic Melanoma
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10053571 Melanoma LLT
    19.0 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-002778-30 Sponsor Protocol Number: GR-2018-12367476 Start Date*: 2022-01-12
    Sponsor Name:IRCCS, OSPEDALE PEDIATRICO BAMBINO GESÙ DI ROMA
    Full Title: Efficacy and safety of memantine as antimanic and mood-stabilizing medication for adolescents with Bipolar Disorder: a multi-center, randomized, double-blind, placebo-controlled clinical trial
    Medical condition: Bipolar Disorder
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10057667 Bipolar disorder PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-001976-75 Sponsor Protocol Number: 20130385 Start Date*: 2014-09-11
    Sponsor Name:Amgen Inc
    Full Title: A Double-Blind, Placebo Controlled, Multicenter Study to Assess the Effect of Evolocumab on Cognitive Function in Patients with Clinically Evident Cardiovascular Disease and Receiving Statin Back...
    Medical condition: Dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004861 10020604 Hypercholesterolemia LLT
    17.0 100000004861 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GR (Completed) IT (Completed) FI (Completed) EE (Completed) SK (Completed) LV (Completed) DE (Completed) LT (Completed) CZ (Completed) PT (Completed) BE (Completed) HU (Completed) DK (Completed) ES (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2014-002605-38 Sponsor Protocol Number: CA224-020 Start Date*: 2015-08-26
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1...
    Medical condition: Neoplasms by site
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065147 Malignant solid tumor LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10053571 Melanoma LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067946 Renal cell carcinoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) AT (Trial now transitioned) FI (Trial now transitioned) GB (GB - no longer in EU/EEA) NO (Trial now transitioned) DK (Trial now transitioned) NL (Trial now transitioned) FR (Trial now transitioned) Outside EU/EEA IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-003542-68 Sponsor Protocol Number: Start Date*: 2016-01-27
    Sponsor Name:University of Oxford
    Full Title: The effect of single-dose losartan on the basic effects of cognitive-behaviour therapy for panic disorder - a randomized double blind placebo-controlled trial
    Medical condition: DSM panic disorder
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004873 10068300 Panic attacks and disorders HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-003828-21 Sponsor Protocol Number: 71617 Start Date*: 2020-02-10
    Sponsor Name:St Antonius Hospital
    Full Title: Identification of sentinel lymph nodes in breast cancer patients through non-invasively and percutaneously fluorescent imaging using indocyanine green
    Medical condition: Axillar staging in breast cancer patients
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002602-12 Sponsor Protocol Number: 16/SEP/6613E Start Date*: 2018-01-12
    Sponsor Name:Cardiff and Vale University Health Board
    Full Title: Improving Transplant Opportunities for Patients who are Sensitised (ITOPS) – a feasibility, randomised, controlled phase III trial
    Medical condition: Highly Sensitised Patients(patients with high levels of human leucocyte antigen specific antibodies) awaiting renal transplantation.These patients are difficult to match to a compatible donor and t...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2021-000588-53 Sponsor Protocol Number: SNIPER Start Date*: 2023-02-07
    Sponsor Name:RIGENERAND Srl
    Full Title: RR001 in combination with chemotherapy for patients with locally advanced pancreatic adenocarcinoma: open-label, non-randomized dose escalation phase I/IIa study
    Medical condition: Locally advanced pancreatic adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073364 Ductal adenocarcinoma of pancreas PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-002156-84 Sponsor Protocol Number: 63623872FLZ3001 Start Date*: 2018-05-08
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-care Treatment in Adolescent, Adult, a...
    Medical condition: Influenza A Infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10022002 Influenza A virus infection LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) LV (Prematurely Ended) LT (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended) SK (Prematurely Ended) BE (Completed) CZ (Prematurely Ended) NL (Prematurely Ended) ES (Prematurely Ended) HU (Prematurely Ended) BG (Prematurely Ended) PL (Prematurely Ended) GB (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-002217-59 Sponsor Protocol Number: 63623872FLZ3002 Start Date*: 2018-05-08
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 3 Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-care Treatment in Adolescent, Adult, ...
    Medical condition: Influenza A Infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10022002 Influenza A virus infection LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) GB (Prematurely Ended) LV (Prematurely Ended) EE (Completed) LT (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended) SK (Prematurely Ended) HU (Prematurely Ended) BE (Completed) BG (Prematurely Ended) CZ (Prematurely Ended) PL (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-003002-17 Sponsor Protocol Number: 63623872FLZ2002 Start Date*: 2015-11-17
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult and Elderly H...
    Medical condition: Influenza A virus infection
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004862 10022002 Influenza A virus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) BE (Completed) DE (Completed) NL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-000574-35 Sponsor Protocol Number: VIS410-201 Start Date*: 2015-04-27
    Sponsor Name:Visterra, Inc.
    Full Title: A Phase 2a Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Antiviral Activity of a Single Intravenous Dose of VIS410 in Healthy Subjects after a Viral Ino...
    Medical condition: Influenza A (H1N1) infection
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004848 10063211 Influenza A virus IgG LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-006236-63 Sponsor Protocol Number: EVT 302/3011 Start Date*: 2008-01-23
    Sponsor Name:Evotec Neurosciences GmbH
    Full Title: A double-blind, randomized, placebo- and NRT-controlled Phase II study to assess the effects of EVT 302 alone and in combination with NRT on craving and withdrawal in healthy male smokers deprived ...
    Medical condition: Smoking cessation. Assessment of the effect of EVT 302 alone or in combination with a nicotine replacement therapy (NRT) on craving and withdrawal in smokers after short-term deprivation of cigare...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10053325 Smoking cessation therapy LLT
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 09:41:05 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA